Butane-Bridge Modified NDGA Derivatives for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nordihydroguaiaretic acid (NDGA) derivatives, such as tetra-O-methyl)nordihydroguaiaretic acid (M4N), face challenges due to poor water solubility and instability, limiting their application in drug action studies and therapeutic use, particularly for viral infections and cancers.
Innovation Solution
Development of butane bridge-modified NDGA derivatives like BB-N and BB-Sb4N, which offer improved water solubility and stability, with specific structural modifications that enhance their potency as antiviral and anticancer agents, including the use of pharmaceutically acceptable salts for enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NDGA derivatives like M4N are used as antiviral and anticancer agents, then they show high potency and effectiveness, but they exhibit poor water solubility which limits their application
Solution Approach 1:
The patent modifies the chemical structure of NDGA derivatives by introducing hydrophilic groups (carboxylic acid, hydroxyl, amino groups) and adjusting the butane bridge substituents to change the solubility parameters while maintaining the core pharmacophore structure responsible for antiviral and anticancer activity
Solution Approach 2:
The patent creates composite molecular structures by combining the hydrophobic NDGA core structure with hydrophilic functional groups and side chains, resulting in amphiphilic derivatives that balance both potency and water solubility characteristics
2Reliability
If NDGA derivatives are used for therapeutic applications, then they show high biological activity, but they exhibit instability which limits their use
Solution Approach 1:
The patent stabilizes NDGA derivatives by modifying the chemical environment through specific substituent groups on the butane bridge and by introducing stabilizing functional groups that protect against metabolic degradation while preserving biological activity
Solution Approach 2:
The patent develops prodrug forms and stable derivatives that can be administered and then metabolized into the active form, allowing the unstable core structure to be delivered in a stable, transportable form that activates only at the target site
3Ease of operation
If NDGA derivatives are modified to improve water solubility, then they become more suitable for drug administration, but their stability decreases
Solution Approach 1:
The patent introduces hydrophilic groups at specific locations (hydroxyl groups on catechol moieties, carboxylic acid groups on side chains) while keeping the core hydrophobic structure intact, creating local polar regions that enhance solubility without compromising overall molecular stability
Data Source
AI summary
The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.